Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A circularly permuted recombinant interleukin 4 toxin with increased activity

R J Kreitman1, R K Puri, I Pastan

  • 1Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

Proceedings of the National Academy of Sciences of the United States of America
|July 19, 1994
PubMed
Summary

Creating circularly permuted interleukin 4 (IL4) fusion proteins enhances receptor binding affinity. This novel approach moves the fusion point, improving recombinant protein effectiveness for targeted therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transfer and expression of the human multidrug resistance gene in mouse erythroleukemia cells.

Blood·1992
Same author

Identification of residues in the first cytoplasmic loop of P-glycoprotein involved in the function of chimeric human MDR1-MDR2 transporters.

The Journal of biological chemistry·1992
Same author

Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol.

The Journal of biological chemistry·1992
Same author

Alanine scanning mutagenesis identifies surface amino acids on domain II of Pseudomonas exotoxin required for cytotoxicity, proper folding, and secretion into periplasm.

The Journal of biological chemistry·1992
Same author

Recombinant toxins containing the variable domains of the anti-Tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia.

Blood·1992
Same author

Pseudomonas exotoxin: recombinant conjugates as therapeutic agents.

Biochemical Society transactions·1992

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Protein Engineering

Background:

  • Fusion proteins are valuable tools in biotechnology.
  • Traditional fusion protein construction often places ligands at the amino or carboxyl terminus.
  • This placement can reduce ligand-receptor binding affinity, compromising protein function.

Purpose of the Study:

  • To engineer a novel fusion protein with improved ligand-receptor binding affinity.
  • To overcome limitations of traditional fusion protein construction methods.
  • To explore the utility of circularly permuted growth factors in recombinant protein design.

Main Methods:

  • Constructed a DNA fragment encoding circularly permuted interleukin 4 (IL4), termed IL4(38-37).
  • Engineered IL4(38-37) by inserting a peptide linker between codons 1 and 129, with altered start and stop codons.

Related Experiment Videos

  • Fused the modified IL4 to a truncated Pseudomonas exotoxin via a new carboxyl terminus.

    • Main Results:

    • The circularly permuted IL4-toxin fusion protein exhibited a 10-fold higher affinity for the IL4 receptor compared to a standard IL4-toxin.
    • Circular permutation successfully relocated the fusion point away from the IL4 receptor binding site.
    • Demonstrated improved binding characteristics of the engineered fusion protein.

    Conclusions:

    • Circularly permuted growth factors represent a significant advancement in recombinant fusion protein design.
    • Relocating the fusion junction can enhance ligand-receptor interactions and protein efficacy.
    • This strategy offers a promising approach for developing more effective targeted protein therapeutics.